301. Discovery of Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus
- Author
-
Jean-Pierre Brincat, Jose L. Raygada, Glenn W. Kaatz, Emanuele Carosati, Gabriele Cruciani, Diixa Patel, Giuseppe Manfroni, Arnaldo Fravolini, and Stefano Sabatini
- Subjects
Models, Molecular ,Staphylococcus aureus ,Quantitative structure–activity relationship ,Databases, Factual ,Quantitative Structure-Activity Relationship ,MRSA ,Microbial Sensitivity Tests ,Drug resistance ,FLAP ,medicine.disease_cause ,NorA ,Microbiology ,Propanolamines ,Structure-Activity Relationship ,Bacterial Proteins ,Ciprofloxacin ,Ethidium ,MDR ,Drug Resistance, Bacterial ,Drug Discovery ,medicine ,Structure–activity relationship ,Efflux Pump ,Sulfonamides ,Virtual screening ,S. aureus ,Chemistry ,Phenyl Ethers ,Drug Synergism ,In vitro ,Anti-Bacterial Agents ,Molecular Medicine ,Benzimidazoles ,Efflux ,Multidrug Resistance-Associated Proteins ,medicine.drug - Abstract
Four novel inhibitors of the NorA efflux pump of Staphylococcus aureus, discovered through a virtual screening process, are reported. The four compounds belong to different chemical classes and were tested for their in vitro ability to block the efflux of a well-known NorA substrate, as well as for their ability to potentiate the effect of ciprofloxacin (CPX) on several strains of S. aureus, including a NorA overexpressing strain. Additionally, the MIC values of each of the compounds individually are reported. A structure-activity relationship study was also performed on these novel chemotypes, revealing three new compounds that are also potent NorA inhibitors. The virtual screening procedure employed FLAP, a new methodology based on GRID force field descriptors.
- Published
- 2010
- Full Text
- View/download PDF